Stockreport

Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics

Ocugen, Inc.  (OCGN) 
PDF MALVERN, Pa.--(BUSINESS WIRE)--Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on innovative therapies that address rare and underse [Read more]